Watson Bio: Adsorbed Tetanus Vaccine Enters Phase III Clinical Trial.

Watson Pharmaceuticals announced that the adsorbed tetanus vaccine independently developed by the company and its subsidiary Yuxi Watson received the Drug Clinical Trial Approval Notice in November 2024 and received the Ethics Review Opinion issued by the Clinical Trial Ethics Review Committee in August 2025. It has now entered Phase III clinical trials.